Half‐life extended factor VIII for the treatment of hemophilia A

This publication has 14 references indexed in Scilit:

• Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A
  Haemophilia, 2014
• A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
  Blood, 2013
• Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A
  Journal of Thrombosis and Haemostasis, 2013
• Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
  Blood, 2012
• Pioneering designs for recombinant coagulation factors
  Thrombosis Research, 2011
• Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
  Blood, 2010
• Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years
  European Journal of Clinical Pharmacology, 2009
• Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
  Journal of Thrombosis and Haemostasis, 2009
• Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
  New England Journal of Medicine, 2007
• Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
  Blood, 2007